Zanzalintinib

Targeted Therapy

Experimental

Not available 2 Clinical Trials

Description

Zanzalintinib is an investigational drug currently being studied in clinical trials for various advanced solid tumors, including colorectal cancer. It is being tested in combination with other immunotherapy drugs like nivolumab, ipilimumab, and relatlimab. These trials are in early phases (Phase 1) and are primarily focused on determining the safety and appropriate dosage of zanzalintinib, as well as looking for early signs of effectiveness. The trials are open-label, meaning both the researchers and participants know who is receiving the drug. Some trials are specifically looking at patients whose tumors have certain characteristics, such as EGFR, VEGF, or VEGFR mutations, or specific levels of PD-L1 expression. Zanzalintinib is not yet approved for treating colorectal cancer.

Mechanism of Action

Zanzalintinib is a targeted therapy. It works by targeting specific proteins involved in the growth and spread of cancer cells. Specifically, it targets VEGFR (Vascular Endothelial Growth Factor Receptor) and other related kinases. By blocking these proteins, zanzalintinib aims to inhibit blood vessel formation (angiogenesis) that tumors need to grow and potentially slow down tumor growth and spread. The specific molecular targets are being further characterized in clinical trials.

Side Effects

As an investigational drug in early-phase clinical trials The full range of side effects for zanzalintinib is still being evaluated. Side effects observed in early trials often include those related to the targeted therapy mechanism (like high blood pressure Fatigue Diarrhea Decreased appetite Nausea Vomiting) and potentially side effects related to the combination with immunotherapy agents (like immune-related adverse events). More specific information about side effects will become available as trials progress. Participants in the trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05176483 Phase 1

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

United States, Australia, Austria, Belgium, France, Germany, Israel, Italy, New

NCT07620574 Phase 3

Not yet recruiting

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Quick Info

Category	Targeted Therapy
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	2

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.